What Researchers Did
This pilot study explored the impact of hyperbaric oxygen therapy (HBOT), delivered in a community setting, on key symptoms experienced by people with long COVID.
What They Found
Participants who completed four weeks of HBOT showed improvements in their fatigue, breathlessness, and overall quality of life. Experiences with the therapy were positive, with individuals perceiving improvements in their significant symptoms.
What This Means for Canadian Patients
For Canadian patients dealing with persistent long COVID symptoms such as chronic fatigue and breathlessness, this preliminary study suggests HBOT could offer a potential short-term benefit. However, this is early research, and HBOT is not yet a standard treatment for long COVID in Canada.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A significant limitation was the difficulty participants faced in regularly attending HBOT sessions due to the ongoing challenges associated with their long COVID condition.